Patents by Inventor Kalpana Sanjay Joshi
Kalpana Sanjay Joshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8906953Abstract: The present invention relates to the use of a compound of formula 1, a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a compound of formula 1 and at least one pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of the compound of formula 1 to a subject in need thereof.Type: GrantFiled: February 26, 2010Date of Patent: December 9, 2014Assignee: Piramal Enterprises LimitedInventors: Kalpana Sanjay Joshi, Sapna Hasit Parikh
-
Patent number: 8895605Abstract: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.Type: GrantFiled: May 3, 2010Date of Patent: November 25, 2014Assignee: Piramal Enterprises LimitedInventors: Maggie Joyce Rathos, Kalpana Sanjay Joshi, Nikhil Krishnamurthy Hebbar, Somesh Sharma
-
Patent number: 8629277Abstract: The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.Type: GrantFiled: February 24, 2011Date of Patent: January 14, 2014Assignee: Piramal Enterprises LimitedInventors: Meenakshi Sivakumar, Kalpana Sanjay Joshi, Valmik Sopan Aware, Ankush Gangaram Sarde, Sandeep Maruti Bagul, Sonal Mohan Manohar
-
Publication number: 20130237582Abstract: The present invention relates to a pharmaceutical combination comprising paclitaxel, or its pharmaceutically acceptable salt; and at least one cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof, for use in the treatment of triple negative breast cancer (TNBC). The present invention relates to a method for the treatment of breast cancer, particularly triple negative breast cancer, by administration to a patient in need thereof, a therapeutically effective amount of a pharmaceutical combination comprising a cytotoxic antineoplastic agent, paclitaxel, and at least one cyclin dependent kinase (CDK) inhibitor; wherein said combination on administration exhibits synergistic effects.Type: ApplicationFiled: November 18, 2011Publication date: September 12, 2013Applicant: Piramal Enterprises LimitedInventors: Maggie Joyce Rathos, Kalpana Sanjay Joshi
-
Publication number: 20130130992Abstract: This invention relates to purified compound of formula (1). The invention includes all isomeric forms and all tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts thereof. The present invention further relates to processes for the production of the compound of formula (1) by fermentation of the fungal strain of sterile mycelium (PM0509732/MTCC5544) and to pharmaceutical compositions containing the compound as active ingredient and its use in medicines for treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: May 23, 2013Applicants: ONCOTEST GMBH, PIRAMAL ENTERPRISES LIMITEDInventors: Sunil Kumar Jaiwant Rao Deshmukh, Shilpa Amit Verekar, Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyil, Kalpana Sanjay Joshi, Heinz-Herbert Fiebig, Gerhard Kelter
-
Publication number: 20130005771Abstract: The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.Type: ApplicationFiled: February 24, 2011Publication date: January 3, 2013Inventors: Meenakshi Sivakumar, Kalpana Sanjay Joshi, Valmik Sopan Aware, Ankush Gangaram Sarde, Sandeep Maruti Bagul, Sonal Mohan Manohar
-
Publication number: 20120316216Abstract: The present invention relates to the use of a compound of formula 1, a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a compound of formula 1 and at least one pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of the compound of formula 1 to a subject in need thereof.Type: ApplicationFiled: February 26, 2010Publication date: December 13, 2012Inventors: Kalpana Sanjay Joshi, Sapna Hasit Parikh
-
Patent number: 8314103Abstract: The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1? (HIF-1?) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1? pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-?.Type: GrantFiled: August 6, 2008Date of Patent: November 20, 2012Assignee: Piramal Enterprises LimitedInventors: Sanjay Kumar, Kalpana Sanjay Joshi, Vijaykumar Deore, Mandar Ramesh Bhonde, Nilambari Nilkanth Yewalkar, Amol Arun Padgaonkar, Asha Adrian Kulkarni-Almeida, Maggie Joyce Rathos, Sapna Parikh, Nilesh Madhukar Dagia
-
Patent number: 8137708Abstract: A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).Type: GrantFiled: February 20, 2007Date of Patent: March 20, 2012Assignee: Piramal Life Sciences LimitedInventors: Kalpana Sanjay Joshi, Vilas Wagh, Somesh Sharma
-
Publication number: 20120046334Abstract: The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.Type: ApplicationFiled: May 3, 2010Publication date: February 23, 2012Inventors: Maggie Joyce Rathos, Kalpana Sanjay Joshi, Nikhil Krishnamurthy Hebbar, Somesh Sharma
-
Publication number: 20110077252Abstract: The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1? (HIF-1?) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1? pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-?.Type: ApplicationFiled: August 6, 2008Publication date: March 31, 2011Inventors: Sanjay Kumar, Kalpana Sanjay Joshi, Vijaykumar Deore, Mandar Ramesh Bhonde, Nilambari Nilkanth Yewalkar, Amol Arun Padgaonkar, Asha Adrian Kulkarni-Almeida, Maggie Joyce Rathos, Sapna Parikh, Nilesh Madhukar Dagia
-
Publication number: 20100028472Abstract: A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).Type: ApplicationFiled: February 20, 2007Publication date: February 4, 2010Applicant: PIRAMAL LIFE SCIENCES LIMITEDInventors: Kalpana Sanjay Joshi, Vilas Wagh, Somesh Sharma
-
Publication number: 20100010002Abstract: The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) wherein X is O, NH, or heterocyclyl; R may be present or absent and if present, is H, alkyl, aryl, or heterocyclyl; in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with GLEEVEC. The invention also relates to a method for reducing the proliferation of cells that are resistant to GLEEVEC by contacting the cells with a compound of general formula (1).Type: ApplicationFiled: August 20, 2007Publication date: January 14, 2010Applicant: Piramal Life Sciences LimitedInventors: Kalpana Sanjay Joshi, Meenakshi Sivakumar, Valmik Sopan Aware, Vilas Sampatrao Wagh, Amit Deshpande, Ankush Gangaram Sarde, Somesh Sharma
-
Patent number: 6159988Abstract: Compounds of formula I, ##STR1## and the physiologically tolerable salts thereof, wherein the substituents R.sub.1 -R.sub.4 have the meanings given in the specifications and show an activity against inflammatory conditions.Type: GrantFiled: June 29, 1998Date of Patent: December 12, 2000Assignee: Hoeschst AktiengesellschaftInventors: Ramachandra Ganapati Naik, Vilas Narayan Mumbaikar, Ravishankar Vasumathy, Aftab Dawoodbhai Lakdawala, Mandakini Bipin Alreja, Bansi Lal, Jurgen Blumbach, Klaus Ulrich Weithmann, Robert Ryder Bartlett, Kalpana Sanjay Joshi, Swati Bal-Tembe, Sadagopan Raghavan
-
Patent number: 6107335Abstract: The compounds 18.beta., 19.beta.-diacetyloxy-18.alpha., 19.alpha.-epoxy-3, 13(16), 14-clerodatrien-2-one (Esculentin A) and 18.beta., 19.beta.-diacetyloxy-18.alpha., 19.alpha.-epoxy-3, 12, 14-clerodatrien-2.beta.-isovaleryloxy-6.beta., 7.alpha.-diol (Esculentin B) obtained from plants belonging to the Samydaceae family, particularly Casearia esculenta, a process for their preparation, and their use in the manufacture of medicaments. The compounds are particularly useful as anti-inflammatory and/or anti-cancer agents.Type: GrantFiled: November 17, 1998Date of Patent: August 22, 2000Assignee: Hoechst Marion Roussel Deutschland GmbHInventors: Swati Bal-Tembe, Erra Koteswara Satya Vijaya Kumar, Vijay Bhagwan Deore, Kalpana Sanjay Joshi